Role brief
Job description
Current Mercor opportunity: Biotech Investment Analyst — Drug Asset & Company Assessment appeared in the live Mercor Explore catalog and was rechecked from the current role page on 2026-09-18.
Mercor is partnering with a biotech and pharma research team on expert human-evaluation work — creating and critiquing rubrics that analyze commercial drugs and drug-development programs. We're seeking a biotech investment analyst (specialist-fund background) for a paid pilot, with the potential to continue as the work scales.
Responsibilities
- Create and critique rubrics that analyze commercial drugs and drug-development programs
- Provide overall company and asset assessment — mechanism, clinical data, competitive position, and value drivers
- Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions
- Apply your assessment across the pilot's set of companies (~5–10)
Requirements
- US-based biotech / healthcare investment analyst with a specialist-fund background
- Familiarity with biotech/pharma development programs
- Able to assess a drug asset and the company behind it end-to-end
- 5+ years evaluating biotech/pharma companies or assets
Engagement Details
- Duration: Approximately 10–20 hours over a 1–2 week pilot
- Remote — US-based
Why Participate
- Help improve expert AI evaluation of drugs and drug-development programs
- Recurring engagement for strong contributors
Current source check: Active on Mercor as of 2026-09-18. Confirm pay, hours, location eligibility, and screening steps in Mercor’s application flow.
Apply through the Mercor link in this listing. WorkAppily is not the hiring employer and does not control role availability or hiring decisions.